Cyclopamine

Catalog No.S1146 Synonyms: 11-deoxojervine

Cyclopamine Chemical Structure

Molecular Weight(MW): 411.62

Cyclopamine is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.

Size Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 370 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 17 Publications

5 Customer Reviews

  • (A)[3H]thymidine incorporation assay of B16F10 melanoma cells treated with DMSO or cyclopamine after incubation with SA-CM from WT and Cav1KO dermal fibroblasts. Representative phase-contrast images of B16F10 cells treated with SA-CM from WT and Cav1KO fibroblasts with cyclopamine are shown on the right. Similar experiments (B) were done with A-375 cells incubated with SA-CM from hTBJ1-shCtrl and hTBJ1-shCAV1 cells.

    Cancer Res 2012 72, 2262-74. Cyclopamine purchased from Selleck.

    (A) The effects of cyclopamine (10 μM) in pancreatic cancer cell invasion. The number of migrated cells was quantified by counting the number of cells from 10 random fields at 200 magnification. (B) The effects of cyclopamine on the expression of EMT-related molecules E-cadherin and vimentin, and Hh pathway-related proteins SMO and Gli-1 were analyzed by Western blotting following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor cyclopamine. Normal culture was used as a negative control. (C) The EMT-related molecules Ecadherin and vimentin mRNA levels, and Hh pathway-related genes at mRNA level were analyzed by real-time RT-PCR following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor Cyclopamine. Normal culture was used as a negative control.

    Cancer Lett 2012 322, 169-176. Cyclopamine purchased from Selleck.

  • Immuofluorescence staining of Gli-1 in MHCC97H cells under normal control or 100 ng/ml CCL2 stimulation or 10 µM Cyc combined with 100 ng/ml CCL2 stimulation for 48 h. Red represents Gli-1 staining. Blue represents nuclear DNA staining by DAPI. Cyc, cyclopamine; CCL2, chemokine (C-C motif) ligand 2.

    Oncol Rep, 2018, 39(1):21-30. Cyclopamine purchased from Selleck.

    (A) Exogenous Shh peptide (500 ng/mL) for 72 hours promoted expansion of CD34+ cells and CD34- cells, cyclopamine (10 μM) for 72 hours induced apoptosis of CD34+ cells and CD34- cells, as measured by 3-(3,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide (MTT) assay, n =4, bars, standard deviation. *Statistically significant compared with CD34+ cells. (B) Exogenous Shh peptide (500 ng/mL) promoted cell expansion after 48 hours and cyclopamine (10 μM) induced cell apoptosis within 24 hours measured by MTT assay (n=6).

    Exp Hematol 2012 40, 418-27. Cyclopamine purchased from Selleck.

  • For MTT assays, cells (2,000 ~ 5,000 cells/well) were subcultured into 96-well plates according to their growth properties. Cell proliferation was assayed at 72 hr after treatment of Cyclopamine by adding 20 μl of 5 mg/ml 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution per 100 μl of growth medium. After incubating for 3-4 h at 37°C, the media were removed and 150 µl/well of MTT solvent (either absolute DMSO or isopropanol containing 4 mM HCl and 0.1% Nonidet-40) was added to dissolve the formazan. The absorbance of each well was measured by ELx808 (BioTek, Winooski, VT) or Wallac Victor2 (Perkin-Elmer Life Sciences, Boston, MA) Microplate Reader. Viable cells are presented as percent of control, vehicle-treated cells.

     

     

    Dr. Yong-Weon Yi from Georgetown University Medical Center. Cyclopamine purchased from Selleck.

Purity & Quality Control

Choose Selective Hedgehog/Smoothened Inhibitors

Biological Activity

Description Cyclopamine is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.
Targets
Smoothened [1]
(TM3Hh12 cells)
46 nM
In vitro

Cyclopamine inhibits the Hedgehog signaling pathway with an IC50 of 46 nM, and blocks the activity of human Smo receptor expressed in CHO-K1 cells in [3H]Hh-Ag binding assay with an IC50 of 280 nM. [1] Cyclopamine significantly inhibits Hedgehog pathway activity in a dose-dependent manner in gut-derived tumor cell lines expressing Patched (PTCH) mRNA, and induces growth inhibition of those tumor cell lines by 75-95% at the concentration of 3 μM, but ineffective towards the colon tumor cells without PTCH mRNA expression, suggesting the effects of Cyclopamine treatment are Hedgehog pathway related rather than generally cytotoxic. [2] By blocking Hedgehog signaling through direct interaction with Smo, Cyclopamine (10 μM) inhibits the proliferation of SMOhigh Cyclopamine-responsive cell lines L3.6sl and Panc 05.04 by 75-80%, and increases the apoptosis by 2.5- to 3.5-fold, without affecting the BxPC3-SMOlow cell line. [3] Cyclopamine treatment significantly decreases of Snail mRNA and increasea E-cadherin transcripts in the E3LZ10.7 cell line. Independent of inhibition of cell growth, Cyclopamine treatment significantly inhibits the invasive phenotype of Hedgehog-dependent L3.6pl cells, causing a >500-fold reduction in the number of transmigrating cells, but not that of the Hedgehog-independent cell line Panc-1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OS-RC-2 Mnu0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTVwOE[2OkDPxE1? Mn\JV2FPT0WU
DOHH-2 NXLKd|J[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LKZmlEPTB;OT6zOVY5QSEQvF2= M2fmOHNCVkeHUh?=
no-10 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTlwOUCzPUDPxE1? MXXTRW5ITVJ?
LS-513 MnXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTFzLkO1OFch|ryP MXPTRW5ITVJ?
ALL-PO NWrneGRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvWSXhKSzVyPUGxMlc4OzRizszN M{jydHNCVkeHUh?=
8-MG-BA NYOwUZhqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmCxTWM2OD1zMz6xNVI{KM7:TR?= MUDTRW5ITVJ?
RPMI-8402 NFzIVpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTF3Lki1N|ch|ryP NV3mSnBmW0GQR1XS
EoL-1-cell MoCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4P6OmlEPTB;MUiuOVk1QCEQvF2= MYTTRW5ITVJ?
NALM-6 MlXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37aZWlEPTB;MUmuNFE3PyEQvF2= NFHhU4FUSU6JRWK=
DEL Mn7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml70TWM2OD1{MD6xOFcyKM7:TR?= NVLWb5FPW0GQR1XS
SR MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTJ|Lk[3NVUh|ryP NIfwZmpUSU6JRWK=
697 NHzUTmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXK1SIVmUUN3ME2yOk43OTV3IN88US=> NHe1UFBUSU6JRWK=
COLO-829 MljjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nBO2lEPTB;Mk[uPFQ5OyEQvF2= MnjZV2FPT0WU
EVSA-T M3fTSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTtU|NYUUN3ME2yO{42PTZzIN88US=> NFXCb49USU6JRWK=
ATN-1 NXvLfWVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHZTWM2OD1|MT6yN|I6KM7:TR?= MnnGV2FPT0WU
L-363 NVHYNplNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PFe2lEPTB;M{GuO|Q3OSEQvF2= NEG4WWlUSU6JRWK=
LAMA-84 NFvKNHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHj[lJ{UUN3ME2zNk42OjFzIN88US=> M2jEZXNCVkeHUh?=
NOS-1 NHWyR|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfONI86UUN3ME2zOE4zQTV4IN88US=> MYHTRW5ITVJ?
BB30-HNC MmrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7O[41KSzVyPUO0MlM{ODZizszN M1ixSHNCVkeHUh?=
BC-1 NUn1bGNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXoV|lVUUN3ME2zO{46PzR4IN88US=> NEnQOXBUSU6JRWK=
IST-SL2 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfYTZR1UUN3ME2zPE4zOjRizszN MlvRV2FPT0WU
D-392MG NEXDUllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHMNIhKSzVyPUSwMlIzOTVizszN NGfKfmpUSU6JRWK=
no-11 MkfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\nXZJKSzVyPUSwMlU2OjFizszN MXjTRW5ITVJ?
LC4-1 NHHmNmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzNNGRuUUN3ME20NE45PzF4IN88US=> MljIV2FPT0WU
A388 NUm2O4FKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPhNI05UUN3ME20Nk42QDR6IN88US=> M1LFWnNCVkeHUh?=
NTERA-S-cl-D1 NVzjPIlkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHn1[29KSzVyPUSyMlcxPzRizszN MYHTRW5ITVJ?
CESS M1fRUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DyV2lEPTB;NESuNlI{OiEQvF2= NH6yZ2NUSU6JRWK=
RS4-11 M2jhbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTR7LkC5N|gh|ryP MmX1V2FPT0WU
MS-1 M1rMe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnQTWM2OD13MD65N|UyKM7:TR?= M3rpSXNCVkeHUh?=
CTV-1 NWPSNo1uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TFXGlEPTB;NUGuNFc1KM7:TR?= M4HLNHNCVkeHUh?=
D-502MG MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fB[GlEPTB;NUGuOlI4OSEQvF2= MVPTRW5ITVJ?
ML-2 NYXESXUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXyco1MUUN3ME21Nk46OTl3IN88US=> MmOwV2FPT0WU
SK-NEP-1 M{nPT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nQV2lEPTB;NUOuN|kzOyEQvF2= MVPTRW5ITVJ?
LOXIMVI NVXQNpdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFj5W3ZKSzVyPUWzMlU5QDRizszN Mn;OV2FPT0WU
DJM-1 NWXyV2FuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHPTWM2OD13Nj6zN|kyKM7:TR?= NFPFNVhUSU6JRWK=
GI-1 NYruVVN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTV4Lk[xOFkh|ryP NH7weVVUSU6JRWK=
IST-MES1 NULwTFJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzzT|NKSzVyPU[wMlU1QTNizszN M{WxWXNCVkeHUh?=
MV-4-11 M1LPcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXW5W3QyUUN3ME22NE43PTN6IN88US=> M3XifHNCVkeHUh?=
OVCAR-4 MnzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTZ|LkW2OVch|ryP NIX2SnlUSU6JRWK=
KE-37 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDIc4pKSzVyPU[2MlI3PjhizszN M{fBdHNCVkeHUh?=
D-542MG NVnXSYhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGriXVRKSzVyPU[4MlQyOzVizszN NISw[XlUSU6JRWK=
MHH-PREB-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPBTWM2OD15Mj64OFQyKM7:TR?= MlTuV2FPT0WU
MRK-nu-1 MmrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPReGNxUUN3ME23N{41PzB3IN88US=> MnjTV2FPT0WU
D-247MG MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXSXoJKSzVyPUezMlU1PDJizszN M{i1dnNCVkeHUh?=
OCI-AML2 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fBPWlEPTB;N{[uPVM3QSEQvF2= NVTQXWl5W0GQR1XS
LP-1 NFT3V5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXGfHhKSzVyPUiyMlg4OzFizszN NV7QPYpOW0GQR1XS
HCC1599 NHzke|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnW5TWM2OD16ND6yPFM4KM7:TR?= MorXV2FPT0WU
KARPAS-45 M33QU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DhV2lEPTB;OESuOlk6OiEQvF2= MkO3V2FPT0WU
BE-13 MnjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTZZ3VKSzVyPUm5MlA1PzdizszN M3fybnNCVkeHUh?=
GCIY M1fMNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHae29KSzVyPUm5MlA6PTRizszN MoX5V2FPT0WU
BV-173 M{\Sdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjDepBKSzVyPUGwNE4{OjVizszN M3\2fnNCVkeHUh?=
LB2518-MEL NUfDZpZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXRS4dKSzVyPUGwNE44QDlizszN M2XNdnNCVkeHUh?=
KS-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\4XGlEPTB;MUCxMlY{QSEQvF2= NVvMWYY{W0GQR1XS
MOLT-16 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPETWM2OD1zMESuPVg3KM7:TR?= NUPkTGNiW0GQR1XS
NCI-H1770 M4fEWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTFyOD63PFQh|ryP MYPTRW5ITVJ?
NCI-H82 NWfV[Jc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HSN2lEPTB;MUGwMlk4PiEQvF2= MojHV2FPT0WU
NCCIT MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn72TWM2OD1zMUKuOVI6KM7:TR?= NFLpcHNUSU6JRWK=
KALS-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTFzNT65OFEh|ryP NELWeHFUSU6JRWK=
LB2241-RCC NFrDWFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vEW2lEPTB;MUG2MlY4QSEQvF2= M4[0U3NCVkeHUh?=
HH NVPlPJB6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\nbYtwUUN3ME2xNVcvOzl3IN88US=> M1nzZXNCVkeHUh?=
HD-MY-Z M4HoOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDWTWM2OD1zMUiuOFg5KM7:TR?= NVq2[WJiW0GQR1XS
EB-3 MlvtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrkTWM2OD1zMkOuNFk1KM7:TR?= M2PCbXNCVkeHUh?=
BL-70 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPYTWM2OD1zMkOuNVI4KM7:TR?= Mn3uV2FPT0WU
K-562 MnHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfZUIZKSzVyPUGyOk4zPDVizszN NWT0[WlyW0GQR1XS
HT-144 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTF|Mz6xOlQh|ryP NGXTWXZUSU6JRWK=
PF-382 M3\5RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXjTWM2OD1zM{SuN|YyKM7:TR?= NVTlVFFIW0GQR1XS
RPMI-8226 NIXGUWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jxT2lEPTB;MUO1MlA1PSEQvF2= MlS1V2FPT0WU
NCI-H1355 NHjrZY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTF|NT61PFch|ryP Ml\VV2FPT0WU
LXF-289 NE\HTIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrxdmtKSzVyPUGzPU44QDFizszN NXS4N2JUW0GQR1XS
NCI-H69 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTF2Mj65N|Ih|ryP NW[3cHVxW0GQR1XS
SK-MEL-1 NGfjZ3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXMTWM2OD1zNEeuNVMh|ryP NGe5UGVUSU6JRWK=
KARPAS-299 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\2TWM2OD1zNEmuNVIh|ryP MV3TRW5ITVJ?
GB-1 M3;0Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\Sc5BKSzVyPUG0PU4{OjJizszN MnrqV2FPT0WU
CMK Ml62S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTGemNTUUN3ME2xOFkvPTF3IN88US=> M{SwTnNCVkeHUh?=
MPP-89 MoG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXwTWM2OD1zNU[uNFM2KM7:TR?= NGG3b2NUSU6JRWK=
KU812 NFfUXoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPQdnlKSzVyPUG2NU46ODJizszN NGHuW3ZUSU6JRWK=
REH NGLSSnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTF4Mj6xNlUh|ryP Mkn6V2FPT0WU
NEC8 Ml\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfjboxIUUN3ME2xOlUvODJ4IN88US=> MXXTRW5ITVJ?
KP-N-YS M1Tib2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rWSWlEPTB;MU[4MlM6PSEQvF2= NIXJO5RUSU6JRWK=
Ramos-2G6-4C10 NXTFWlZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrJd5pKSzVyPUG2PU46OTVizszN NU\u[oZ[W0GQR1XS
Becker NUnocJMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nXOmlEPTB;MUe0MlE5KM7:TR?= MUTTRW5ITVJ?
LB647-SCLC NF7MfJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnyNIl2UUN3ME2xO|UvQDR3IN88US=> MnTpV2FPT0WU
LU-139 M2e2cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTF5OD6wNVkh|ryP MXHTRW5ITVJ?
QIMR-WIL NED5XFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\SR2lEPTB;MUe5MlY1PiEQvF2= NHvMRmRUSU6JRWK=
NCI-H1395 M{TGUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTF5OT65PVYh|ryP MoTvV2FPT0WU
NOMO-1 MoLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEG2TJRKSzVyPUG4Nk45PSEQvF2= NInpdZlUSU6JRWK=
GI-ME-N NWjuOWFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknITWM2OD1zOEeuPVY6KM7:TR?= NGr3dW9USU6JRWK=
KMS-12-PE NIP6bnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHuxdopKSzVyPUG4PU4zPzNizszN MUfTRW5ITVJ?
Daudi MmDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfJXGpKSzVyPUG5NU4yOjhizszN NF7BUW1USU6JRWK=
LB996-RCC MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrY[2dKSzVyPUG5NU43QTlizszN NHHqemhUSU6JRWK=
NCI-H2107 M2LqXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfoelZKSzVyPUG5N{44OzlizszN NYDXc45CW0GQR1XS
SK-PN-DW MmrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zrU2lEPTB;MUm0MlcyQSEQvF2= M{H1d3NCVkeHUh?=
MC-CAR M4\qUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTJyMj6yOVMh|ryP MkLsV2FPT0WU
SNB75 NV7DZ4tJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTJ{MT65OEDPxE1? MkXwV2FPT0WU
ES4 NX3tSlF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHFTWM2OD1{MkOuO|g{KM7:TR?= MVnTRW5ITVJ?
KARPAS-422 NHmyfHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTJ{OD6zOVIh|ryP MWrTRW5ITVJ?
NCI-H1648 NF;LOFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWW1dVVvUUN3ME2yNlkvPDh7IN88US=> Mn\yV2FPT0WU
ES6 NVLicmdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\4V2lEPTB;MkO5MlQ{KM7:TR?= MofvV2FPT0WU
KNS-81-FD MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXG5[WhoUUN3ME2yOFEvOTl5IN88US=> NH23eIVUSU6JRWK=
JAR M2qwVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3ITWM2OD1{NU[uNlI2KM7:TR?= NETLO2JUSU6JRWK=
NB1 M{XqV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDlTWM2OD1{NkCuOVE3KM7:TR?= Mo\EV2FPT0WU
D-336MG MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\aUolKSzVyPUK2NE43QThizszN MnTjV2FPT0WU
BC-3 M2\DSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYmzSYhZUUN3ME2yOlUvOTd6IN88US=> MV\TRW5ITVJ?
HCC2218 NWrI[|VRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rtSGlEPTB;Mk[2MlQyPSEQvF2= NWPFRplyW0GQR1XS
TE-9 NXrLRWkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7ob|VRUUN3ME2yOlYvPjJ5IN88US=> MVnTRW5ITVJ?
LB1047-RCC NYjz[2ZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;kTWM2OD1{Nk[uO|U{KM7:TR?= NID2fW1USU6JRWK=
CTB-1 NYizc2Q3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTJ4OT65O|Mh|ryP Mm\aV2FPT0WU
NB7 NFnGSFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTJ5MTFOwG0> Mmm3V2FPT0WU
ST486 NXj4N|R6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFW1W|JKSzVyPUK3O{41OTJizszN M2jyb3NCVkeHUh?=
HCC1187 M3r0NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfFN5dKSzVyPUK4Nk45OTFizszN M1;pdnNCVkeHUh?=
NCI-SNU-16 NH3xeXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDNPGlKSzVyPUK4OE4zPDhizszN NG\UTGVUSU6JRWK=
COR-L279 M{TJfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXC[XZKSzVyPUK5NU42QDRizszN MWDTRW5ITVJ?
ES8 NGj1bldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2X0WGlEPTB;Mkm0MlE5OiEQvF2= MVLTRW5ITVJ?
U-698-M NGHxeWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDrSoZmUUN3ME2yPVgvOjR|IN88US=> NIHFdoRUSU6JRWK=
HEL MkTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTNyOT6xOFkh|ryP MmTYV2FPT0WU
KINGS-1 NYLIUlJCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXzTWM2OD1|MUCuOlc1KM7:TR?= NIj5dmZUSU6JRWK=
KY821 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHQWW1KSzVyPUOzOk42QTVizszN MlG2V2FPT0WU
MZ1-PC MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTN2NT62NVgh|ryP NUDENWRPW0GQR1XS
LS-411N M3LFPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTN3ND62OkDPxE1? MnHoV2FPT0WU
SIG-M5 MlzBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITIcmtKSzVyPUO1PU44QDJizszN MmPsV2FPT0WU
HT M1j1WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTN4Nz63NVEh|ryP NF7SZ25USU6JRWK=
HC-1 MnLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLYTWM2OD1|NkeuO|g4KM7:TR?= MlrQV2FPT0WU
NCI-H1694 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvrR2FKSzVyPUO3Nk46OzRizszN M{\KUnNCVkeHUh?=
BB65-RCC NHvZXHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\DR3hMUUN3ME2zO|YvOjR3IN88US=> MYPTRW5ITVJ?
HAL-01 NU[zR|lXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\Db5J2UUN3ME2zO|kvQDN6IN88US=> NX\ESXd4W0GQR1XS
ARH-77 NEPM[mhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTN7ND6wNFgh|ryP MkDMV2FPT0WU
MZ7-mel NIW0V2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTN7Nz6yN|Mh|ryP NWLGb5Y1W0GQR1XS
SIMA MoL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2izOmlEPTB;NECzMlk{OyEQvF2= MV3TRW5ITVJ?
DG-75 M3H2O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfmTWM2OD12MUWuOlk5KM7:TR?= M4XFOnNCVkeHUh?=
HUTU-80 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTRzOT6xPFUh|ryP NH\xXoVUSU6JRWK=
KNS-42 MmOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTR{NT64NVUh|ryP MX3TRW5ITVJ?
SH-4 M1r3W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvGTWM2OD12MkeuOVY2KM7:TR?= MoCxV2FPT0WU
L-540 M4fPNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nOd2lEPTB;NEOxMlA{OSEQvF2= M{\lNHNCVkeHUh?=
NB10 M33yemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEWyZ2pKSzVyPUS0NU4zOzRizszN NYHRPZpUW0GQR1XS
ES1 M4\Ve2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITjdY9KSzVyPUS1Nk44PTNizszN MkL0V2FPT0WU
KMOE-2 NGXWU4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLpc|B7UUN3ME20OVYvPzFzIN88US=> MlPsV2FPT0WU
MC116 NFW5dINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPuN29KSzVyPUS1PE4yOTZizszN NGjyW4xUSU6JRWK=
RCC10RGB MlPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NED3VZZKSzVyPUS2NE4xODVizszN NGG3[VZUSU6JRWK=
RL95-2 NUDDeIZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTR4MD6yN|ch|ryP MmLtV2FPT0WU
Raji MlroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrjVG1KSzVyPUS2PE4yPDNizszN MoH2V2FPT0WU
CAS-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFX5VY9KSzVyPUS3Nk4xPzNizszN Mk\vV2FPT0WU
Calu-6 NFHvfFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTR5NT6yOlUh|ryP NV\xSolRW0GQR1XS
KG-1 NUKzNZczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvyOJdLUUN3ME20O|gvPDRizszN NHPpeI9USU6JRWK=
LB771-HNC MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoK5TWM2OD12OEKuNlMzKM7:TR?= MUjTRW5ITVJ?
ACN M1nKdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlftTWM2OD12OUOuOVk6KM7:TR?= M{LiNHNCVkeHUh?=
KM12 NUXqWFhCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXOSIVJUUN3ME20PVYvPTh7IN88US=> NWW2[YN5W0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Administration of Cyclopamine at dose of 50 mg/kg/day for 22 days eradicates the HUCCT1 xenografts in mice with no obvious adverse effects. [2] Cyclopamine treatment at dose of 1.2 mg for 7 days induces significant apoptosis of tumor cells and decreases the tumor mass by 50-60% in Panc 05.04- and L3.6sl-derived tumors, respectively, but not in the BxPC3-SMOlow tumors. [3] Administration of Cyclopamine alone profoundly inhibits tumor metastases in xenografts of E3LZ10.7 and L3.6pl, and completely abrogates metastases when in combination of gemcitabine. [4]

Protocol

Kinase Assay:[1]
+ Expand

Hedgehog cell assay:

This assay measures the end stage of the Hh signaling pathway, that is, the transcriptional modulation of Gli, using Luciferase as readout (Gli-Luc assay). Cyclopamine is prepared for assay by serial dilution in DMSO and then added to empty assay plates. TM3Hh12 cells (TM3 cells containing Hh-responsive reporter gene construct pTA-8xGli-Luc) are resuspended in F12 Ham's/DMEM (1:1) containing 5% FBS and 15 mM Hepes pH 7.3, added to assay plates and incubated with Cyclopamine for approximately 30 minutes at 37 °C in 5% CO2. 1 nM Hh-Ag 1.5 is then added to assay plates and incubated at 37 °C in the presence of 5% CO2. After 48 hours, either Bright-Glo or MTS reagent is added to the assay plates and luminescence or absorbance at 492 nm is determined. IC50 value, defined as the inflection point of the logistic curve, is determined by non-linear regression of the Gli-driven luciferase luminescence or absorbance signal from MTS assay vs log10 (concentration) of Cyclopamine using the R statistical software pack
Cell Research:[2]
+ Expand
  • Cell lines: SEG1, OE33, KYAE, KYSE180, SNU1, AGS, SNU16, NCI-N-87, HUCCT1, PANC1, PL5, PL6, BXPC3, HS766T, KYSE150, GBD1, DLD1, and HCT116
  • Concentrations: Dissolved in DMSO, final concentration 3 μM
  • Incubation Time: 4 days
  • Method: Cells are exposed to Cyclopamine in 96-well plates. Cell viability is measured by MTS (soluble tetrazolium salt) assay. Viable cell mass is determined by optical density measurements at 490 nm (OD490) at 2 and 4 days using the CellTiter96 colorimetric assay. Relative growth is calculated as OD (day 4)﹣OD (day 2)/OD (day 2).
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Athymic (nude) mice inoculated subcutaneously with HUCCT1 cells
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: 50 mg/kg/day
  • Administration: Subcutaneous injection
    (Only for Reference)

Solubility (25°C)

In vitro DMF 10 mg/mL warmed (24.29 mM)
Ethanol 2 mg/mL warmed (4.85 mM)
DMSO Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 411.62
Formula

C27H41NO2

CAS No. 4449-51-8
Storage powder
in solvent
Synonyms 11-deoxojervine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to reconstitute the compound for in vivo use in mice?

  • Answer:

    One paper dissolved this drug in DMSO, and diluted in saline: Berman DM, et al. Nature, 2003, 425(6960), 846-851. Alternatively, you can try this vehicle: 10% DMSO+30% PEG 300+5% Tween 80+ddH2O for P.O. When preparing the solution, please dissolve the compound in DMSO clearly first. Then add PEG300 and Tween, after they mixed well, dilute with water.

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

Related Hedgehog/Smoothened Products4

Tags: buy Cyclopamine | Cyclopamine supplier | purchase Cyclopamine | Cyclopamine cost | Cyclopamine manufacturer | order Cyclopamine | Cyclopamine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID